The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | CAR-T vs CAR-NK for myeloma
Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, gives an overview of the pros and cons of chimeric antigen receptor T-cell (CAR-T) therapy in comparison to CAR-natural killer (CAR-NK) cell therapy. CAR-T therapies have shown extensive clinical success in multiple hematological malignancies, whereas there is very limited data on the efficacy of CAR-NK cells. While there has been some successful clinical application of CAR-NK cells in the treatment of lymphoma, the mechanisms of persistence and migration in the tumor tissue remain unclear, meaning that this is currently a severely limited treatment option for myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
